A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
== Universities == According to the 2020 QS World University Rankings, Chulalongkorn University (CU) was ranked 247th in the world and earned the top ranking in Thailand for the seventh consecutive year. Also ranked were Mahidol University (314th), and Chiang Mai University and Thammasat University (both in the 601–650 tranche), and four other Thai universities in the 801–1,000 tranche. The Times Higher Education Asia University Rankings 2018 ranked Mahidol University as the top Thai institution. It ranked 97 of some 350 universities (1=best; 350=lowest). King Mongkut's University of Technology Thonburi was ranked 116, Chulalongkorn University 164, and Suranaree University of Technology 168. Thailand had no other universities in the top 200. Chulalongkorn University was ranked number one in Thailand and 45th in Asia in 2016. Mahidol University was ranked the top Thai university among the top 200 Asian (including Middle Eastern) universities in 2016 by Times Higher Education Asia University Rankings 2016.
Surgical technique – the bilobed flap The design of the bilobed flap co-ordinates its lobes with the long axis of the nasal defect (wound); each lobe of the flap is emplaced at a 45-degree angle to the axis. The two lobes of the bilobed flap rotate along an arc, of which all points are equidistant from the apex of the nasal defect.
In March 2002, Yorkshire merged with Tricon Global Restaurants to form Yum! Brands. A few weeks later, Malaysian company KUB took over the franchises in Southeast Asia, aiming to restore its prestige in Malaysia alone and increasing its market share. Subsequently, in January 2003, Yum! announced that A&W and Long John Silver's would move their operational base from Lexington to Louisville, as operating the chains from Lexington was considered "impractical and cost-inefficient", preferring to operate all of its chains from Louisville. Under Yum's management, A&W added franchises with a nostalgic look and modern technology. They have a carhop design with drive-thrus, and some have picnic tables. The chain didn't seek to compete against McDonald's, instead preferring to carve up its own niche. 2004 saw the return of the Papa Burger brand at a restaurant in Dayton - the Burger Family brand originally retired in the United States in the 1980s, being replaced by the Deluxe Burgers - and was the only name of the old line that was reinstated, with the other burgers having new names. In September 2001 the Singapore branch was taken over by KUB, who also oversaw the restaurants in Malaysia. At the time of takeover, it had twelve restaurants, but by November 2002, the number had dwindled to eight. Its restaurants had already been downgraded: the Ang Mo Kio restaurant shut down, the Tampines restaurant refused to repair its air conditioning systems, and cable TV was switched off in all outlets. Food sales had decreased by about 5-12%.
Sources: en.wikipedia.org
The "d-" in the name d-ribose refers to the stereochemistry of the chiral carbon atom farthest away from the aldehyde group (C4'). In d-ribose, as in all d-sugars, this carbon atom has the same configuration as in d-glyceraldehyde.Relative abundance of forms of ribose in solution: β-d-ribopyranose (59%), α-d-ribopyranose (20%), β-d-ribofuranose (13%), α-d-ribofuranose (7%) and open chain (0.1%). For ribose residues in nucleosides and nucleotides, the torsion angles for the rotation encompassing the bonds influence the configuration of the respective nucleoside and nucleotide. The secondary structure of a nucleic acid is determined by the rotation of its 7 torsion angles. Having a large amount of torsion angles allows for greater flexibility. In closed ring riboses, the observed flexibility mentioned above is not observed because the ring cycle imposes a limit on the number of torsion angles possible in the structure. Conformers of closed form riboses differ in regards to how the lone oxygen in the molecule is positioned respective to the nitrogenous base (also known as a nucleobase or just a base) attached to the ribose. If a carbon is facing towards the base, then the ribose is labeled as endo. If a carbon is facing away from the base, then the ribose is labeled as exo. If there is an oxygen molecule attached to the 2' carbon of a closed cycle ribose, then the exo confirmation is more stable because it decreases the interactions of the oxygen with the base.
==== Supplements ==== Avocado–soybean unsaponifiables (ASU) is an extract made from avocado oil and soybean oil sold under many brand names worldwide as a dietary supplement and as a prescription drug in France. A 2014 Cochrane review found that while ASU might help relieve pain in the short term for some people with osteoarthritis, it does not appear to improve or maintain the health of affected joints. The review noted a high-quality, two-year clinical trial comparing ASU to chondroitin – which has uncertain efficacy in osteoarthritis – with no difference between the two agents. The review also found there is insufficient evidence of ASU safety. Only a few moderate-quality studies of Boswellia serrata showed small improvements in pain and function. Curcumin and s-adenosyl methionine (SAMe) showed little effect in improving pain. A 2009 Cochrane review recommended against the routine use of SAMe, as there has not been sufficient high-quality clinical research to prove its effect. A 2021 review found that hydroxychloroquine (HCQ) had no benefit in reducing pain and improving physical function in hand or knee osteoarthritis, and the off-label use of HCQ for people with osteoarthritis should be discouraged. There is no evidence for the use of colchicine for treating the pain of hand or knee arthritis. There is limited evidence to support the use of hyaluronan, methylsulfonylmethane, rose hip, capsaicin, or vitamin D.
== In popular culture == The 1896 Gilbert and Sullivan operetta The Grand Duke features sausage rolls as a plot device, where conspirators recognise one another by eating sausage rolls. From 2018 to 2022, English YouTuber LadBaby had five consecutive Christmas number ones on the UK Singles Chart with cover versions of songs where the lyrics were rewritten to reference sausage rolls, including "I Love Sausage Rolls", "Don't Stop Me Eatin'", and "Sausage Rolls for Everyone".
== Clinical significance == A disease of the entheses is known as an enthesopathy or enthesitis. Enthetic degeneration is characteristic of spondyloarthropathy and other pathologies. The enthesis is the primary site of disease in ankylosing spondylitis.
Sources: en.wikipedia.org
The ISOLDE facility contains the Class A laboratories, buildings for the HIE-ISOLDE and MEDICIS projects, and the control rooms located in building 508. Before ISOLDE, the radioactive nuclides were transported from the production are to the laboratory for examination. At ISOLDE, all processes from the production to the measurements are connected and the radioactive material requires no extra transport. Due to this, ISOLDE is referred to as an on-line facility. At the ISOLDE facility, the main proton beam for reactions comes from the PSB. The incoming proton beam has an energy of 1.4 GeV and its average intensity varies up to 2 μA. The beam enters the facility and is directed towards one of two mass separators: the General Purpose Separator (GPS) and the High Resolution Separator (HRS). The separators have independently run target-ion source systems, delivering 60 keV RIBs.
The mechanism by which pertechnetate prevents corrosion is not well understood, but seems to involve the reversible formation of a thin surface layer (passivation). One theory holds that the pertechnetate reacts with the steel surface to form a layer of technetium dioxide which prevents further corrosion; the same effect explains how iron powder can be used to remove pertechnetate from water. The effect disappears rapidly if the concentration of pertechnetate falls below the minimum concentration or if too high a concentration of other ions is added. As noted, the radioactive nature of technetium (3 MBq/L at the concentrations required) makes this corrosion protection impractical in almost all situations. Nevertheless, corrosion protection by pertechnetate ions was proposed (but never adopted) for use in boiling water reactors.
== Gameplay == Each player controls a base that represent that player's life pool, and is able to obtain another base if theirs is destroyed. The object is to destroy three bases to win the game, which is achieved by attacking the opposing player. On their turn, a player uses the resources from the five cards in their hand to obtain new cards from a central "galaxy row", which contains cards of the Empire and Rebel factions. The player may only select from cards of their faction, and the galaxy row is reconstituted with cards from the "galaxy deck". One innovate game mechanic is the ability of a player to attack cards still in the galaxy row before they have been obtained by other players, known as sabotage for the Rebel faction and bounty hunting for the Empire faction. These provide a reward to the player taking that action, and also deny other players from obtaining targeted cards. Throughout the game, a Force meter records the balance in the Force, which may alter the effect of cards in favour of a particular faction.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.